Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437839 | 0.93 | CYP11B2 (0.35) | CYP11B1CYP11B2NR3C1GRM1CYP17A1 | |
| SCHEMBL2006894 | 0.86 | NR3C1 (0.38) | CYP11B1CYP11B2NR3C1ESR1CYP17A1 | |
| SCHEMBL2005767 | 0.83 | ESRRA (0.36) | CYP11B1CYP11B2NR3C1GRM1ESR1 | |
| SCHEMBL2008360 | 0.83 | NR3C1 (0.35) | CYP11B1CYP11B2NR3C1GRM1ESR1 | |
| SCHEMBL2009185 | 0.83 | CYP11B1 (0.39) | CYP11B1CYP11B2NR3C1HTTSMN1; SMN2 | |
| SCHEMBL2006268 | 0.83 | TRPA1 (0.35) | CYP11B1CYP11B2NR3C1SMN1; SMN2ESR1 | |
| SCHEMBL2004925 | 0.80 | ESR1 (0.37) | CYP11B1CYP11B2NR3C1ESR1 | |
| SCHEMBL2002221 | 0.80 | PGR (0.40) | CYP11B2NR3C1ESR1 | |
| SCHEMBL12572492 | 0.80 | ESR1 (0.33) | CYP11B1CYP11B2NR3C1ESR1 | |
| SCHEMBL2008964 | 0.80 | CYP11B1 (0.45) | CYP11B1CYP11B2NR3C1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | claimed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| EP-2118068-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GPER1, ESR2, ESRRB | CYP11B1 20/4885CYP11B2 14/4885NR3C1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.